USPTO serial 78723291
PROXIMAGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 20, 2008
- Examiner
- KEAN, AMY C
- Law office
- GENERIC WEB UPDATE
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with PROXIMAGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, GB
London, GB
London, GB
London, GB
LONDON, GB
PLYMOUTH, MN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Frances M. Jagla
Frances M. Jagla Lane Powell PC601 S.W. Second Avenue, Suite 2100Portland, OR 97204UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical preparations and substances, namely: analgesics; anesthetics, namely, anesthetics for surgical purposes, general anesthetics, local anesthetics, inhalant anesthetics, and topical anesthetics; anti-emetics; antiepileptics; antineuralgics; antipyretics; antirheumatics; antispasmodics; aphrodisiacs; cardiac, cerebral and hepatic restoratives, namely, analgesics, anti-virals, and anti-inflammatories; cardiac sedatives; cardiac stimulants; cerebral depressants; cerebral stimulants; depressants; digestives; diuretics; emetics; hypnotics; motor depressants; motor excitants, namely, amphetamines, anti-depressants, and psychomotor stimulants, namely, amphetamines; narcotics; nervines; respiratory depressants; respiratory stimulants; sedatives; soporifics, namely, sedatives; stimulants, namely, appetite stimulants, cognitive enhancing agents, namely, neurostimulants, nerve cell growth stimulators and respiratory stimulants; vaso-constrictors; vasodilators; and vascular sedatives; and pharmaceutical preparations and substances for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control ] | SECTION 8 - CANCELLED | — |
| 042 | Pharmaceutical research and development services; Product research and development services; Research and development of vaccines and medicines; Research services for others in the fields of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; evaluation and testing of compounds for medical purposes, namely analgesics, anesthetics, namely anesthetics for surgical purposes, general anesthetics, local anesthetics, inhalant anesthetics, and topical anesthetics, anti-emetics, antiepileptics, antineuralgics, antipyretics, antirheumatics, antispasmodics, aphrodisiacs, cardiac, cerebral and hepatic restoratives, namely analgesics, anti-virals, and anti-inflammatories, cardiac sedatives, cardiac stimulants, cerebral depressants, cerebral stimulants, depressants, digestives, diuretics, emetics, hypnotics, motor depressants, motor excitants, namely amphetamines, anti-depressants, and psychomotor stimulants, namely, amphetamines, narcotics, nervines, respiratory depressants, respiratory stimulants, sedatives, soporifics, namely sedatives, stimulants, namely appetite stimulants, cognitive enhancing agents, namely, neurostimulants, nerve cell growth stimulators and respiratory stimulants, vaso-constrictors, vasodilators, and vascular sedatives in the fields of Research of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Licensing of intellectual property; Information services in relation to the fields of research of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Advisory and consultation services in the fields of research of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control | ACTIVE | — |
| 044 | Information services in relation to the fields of treatment of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Information services in relation to analgesics, anesthetics, namely anesthetics for surgical purposes, general anesthetics, local anesthetics, inhalant anesthetics, and topical anesthetics, anti-emetics, antiepileptics, antineuralgics, antipyretics, antirheumatics, antispasmodics, aphrodisiacs, cardiac, cerebral and hepatic restoratives, namely analgesics, anti-virals, and anti-inflammatories, cardiac sedatives, cardiac stimulants, cerebral depressants, cerebral stimulants, depressants, digestives, diuretics, emetics, hypnotics, motor depressants, motor excitants, namely amphetamines, anti-depressants, and psychomotor stimulants, namely, amphetamines, narcotics, nervines, respiratory depressants, respiratory stimulants, sedatives, soporifics, namely sedatives, stimulants, namely appetite stimulants, cognitive enhancing agents, namely, neurostimulants, nerve cell growth stimulators and respiratory stimulants, vaso-constrictors, vasodilators, and vascular sedatives; Treatment of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Information services in relation to the fields of treatment of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Advisory and consultation services in the fields of treatment of the alimentary tract and metabolism, blood and blood forming-organs, the cardiovascular system, the endocrine system, the musculoskeletal system, the peripheral nervous system, the genitourinary system, the respiratory system, the reproductive system, the central nervous system, the neurological system, and for psychiatric and psychological disorders, neurodegenerative diseases, cancer, and pain relief and control; Advisory and consultation services in relation to analgesics, anesthetics, namely anesthetics for surgical purposes, general anesthetics, local anesthetics, inhalant anesthetics, and topical anesthetics, anti-emetics, antiepileptics, antineuralgics, antipyretics, antirheumatics, antispasmodics, aphrodisiacs, restoratives, namely analgesics, anti-virals, and anti-inflammatories, cardiac sedatives, cardiac stimulants, cerebral depressants, cerebral stimulants, depressants, digestives, diuretics, emetics, hypnotics, motor depressants, motor excitants, namely amphetamines, anti-depressants, and psychomotor stimulants, namely, neurostimulants, narcotics, nervines, respiratory depressants, respiratory stimulants, sedatives; Medical testing and diagnostic services; Provision of medical and pharmaceutical information; and Medical and pharmaceutical consultation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Proximagen Neuroscience Plc
- Other trademarks owned by Proximagen Neuroscience Plc
- Other trademarks owned by Proximagen Neuroscience Plc
- Other trademarks owned by Proximagen Group Limited
- Other trademarks owned by PROXIMAGEN GROUP LTD.
- Other trademarks owned by PROXIMAGEN, LLC
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PROXIMAGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 17, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 8, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 7, 2018 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Aug 7, 2018 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Aug 7, 2018 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Aug 3, 2018 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| May 20, 2017 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Jun 5, 2014 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jun 5, 2014 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jun 4, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 20, 2014 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| May 20, 2014 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| May 20, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 14, 2008 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Apr 9, 2008 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 9, 2008 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 13, 2007 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 21, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 1, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Jul 19, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 16, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 16, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 16, 2007 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 16, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 16, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 16, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 10, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 10, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 10, 2007 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 10, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 10, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 9, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 9, 2007 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 9, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 9, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 5, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 5, 2007 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 5, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 5, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 15, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 15, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2007 | ALIE | ASSIGNED TO LIE | — |
| May 21, 2007 | PAPER RECEIVED | — | |
| Nov 27, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 10, 2006 | PAPER RECEIVED | — | |
| Oct 4, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 6, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 6, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 3, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Feb 2, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2006 | PAPER RECEIVED | — | |
| Oct 4, 2005 | NWAP | NEW APPLICATION ENTERED | — |